The 5A6A polymorphism in the promoter of the stromelysin-1 (MMP3) gene as a risk factor for restenosis

European Heart Journal

Volumn 23, Issue 9, 2002, Pages 721-725

  Humphries, Steve ^a,d   Bauters, C ^b,c   Meirhaeghe, A ^b   Luong, L ^a   Bertrand, M ^c   Amouyel, P ^b,c  

^a Rayne Institute ^*  (United Kingdom)

^b INSTITUT PASTEUR DE LILLE   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Genetic polymorphism; Restenosis; Stent; Stromelysin (MMP 3); Vascular remodelling

Indexed keywords

ADENOSINE; MATRIX METALLOPROTEINASE; STROMELYSIN;

ADULT; ARTICLE; CARDIOVASCULAR RISK; DNA POLYMORPHISM; ENZYME ACTIVITY; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROMOTER REGION; RESTENOSIS; STENT;

AGED; ALLELES; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BLOOD VESSEL PROSTHESIS IMPLANTATION; CORONARY RESTENOSIS; CORONARY STENOSIS; FEMALE; FOLLOW-UP STUDIES; FRANCE; GENOTYPE; HUMANS; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RISK FACTORS; STENTS;

EID: 0036558722     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2001.2895     Document Type: Article

References (18)

1. McBride W, Lange RA, Hillis LD. Restenosis after successful coronary angioplasty. Pathophysiology and prevention. N Engl J Med 1988; 318: 1734-7.
2. Serruys PW, de Jaegere P, Kiemeneij F et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994; 331: 489-95.
3. Bauters C, Amouyel, Bertrand ME. ACE gene polymorphism and coronary restenosis. Semin Interv Cardiol 1999; 4: 145-9.
4. Mintz GS, Popma JJ, Pichard AD et al. Arterial remodeling after coronary angioplasty: A serial intravascular ultrasound study. Circulation 1996; 94: 35-43.
5. Newby AC, Southgate KM, Davies M. Extracellular matrix degrading metalloproteinase in the pathogenesis of arteriosclerosis. Bas Res Cardiol 1994; 89: 59-70.
6. Henney AM, Wakeley P, Davies MJ et al. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci USA 1991; 88: 8154-8.
7. Galis JS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94: 2493-503.
8. Murphy G, Reynolds JJ. Extracellular matrix degradation. In: Royce PM, Steinman B, eds. Connective Tissue and Its Heritable Disorders. New York: Wiley-Liss, Inc. 1993: 287.
9. Quinones S, Buttice G, Kurkinen M. Promoter elements in the transcriptional activation of the human stromelysin-1 gene by the inflammatory cytokine, interleukin 1. Biochem J 1994; 302: 471-7.
10. Ye S, Watts GF, Mandalia S, Humphries SE, Henney AM. Preliminary report: Genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J 1995; 73: 209-15.
11. Ye S, Eriksson P, Hamsten A, Kirkinen M, Humphries SE, Henney AM. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem 1996; 271: 13 055-60.
12. Humphries SE, Luong L-A, Talmud PJ et al. The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study. Atherosclerosis 1998; 139: 49-56.
13. de Maat MPM, Jukema W, Ye S et al. Efficacy of pravastatin treatment in coronary atherosclerosis is modulated by natural variation in the stromelysin-1 promoter. Am J Cardiol 1999; 83: 852-6.
14. Hamon M, Bauters C, Amant C et al. Relation between the deletion polymorphism of the angiotensin-converting enzyme gene and late luminal narrowing after coronary angioplasty. Circulation 1995; 92: 296-9.
15. Amant C, Bauters C, Bodart JC et al. The D allele of the angiotensin I-converting enzyme is a major risk factor for restenosis after coronary stenting. Circulation 1997; 96: 56-60.
16. Gurlek A, Gulec S, Karabulut H et al. Relation between the insertion/deletion polymorphism of the angiotensin I converting enzyme gene and restenosis after coronary stenting. J Cardiovasc Risk 2000; 7: 403-7.
17. Koch W, Kastrati A, Mehilli J, Bottiger C, von Beckerath N, Schomig A. Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene is not associated with restenosis after coronary stent placement. Circulation 2000; 102: 197-202.
18. Terashima M, Akita H, Kanazawa K et al. Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction. Circulation 1999; 99: 2717-9.